Skip to main content
OpenTrials

Clinical trial condition

Refractory Acute Myeloid Leukemia

Explore clinical trials studying Refractory Acute Myeloid Leukemia. Study availability and eligibility vary by location and protocol.

100 public trials 42 recruiting studies
Refine in advanced search Browse all conditions

Refractory Acute Myeloid Leukemia trial results

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

NCT06222580

Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, +9 more
Locations
  • UNC Hospitals, University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
  • University of Wisconsin Carbone Cancer Center Madison, Wisconsin, United States
View Trial Details
Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067

Conditions
Acute Leukemia of Ambiguous Lineage, Hematologic Diseases, Hemic and Lymphatic Diseases, +13 more
Locations
  • Rady Children's Hospital San Diego, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • Children's Mercy Hospital of Kansas City Kansas City, Missouri, United States
View Trial Details
Recruiting

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

NCT06834282

Conditions
AML, Acute Myeloid Leukemia, Hematologic Diseases, +7 more
Locations
  • University of California, Davis Comprehensive Cancer Center Sacramento, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Sarah Cannon Research Insitute Nashville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT03471260

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +13 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Oregon Health and Science University Portland, Oregon, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions